GLP-1 Agents May Reduce Psoriasis Severity
National Psoriasis Foundation review highlights limited evidence and potential metabolic links.
-
By
-
Andrea Surnit
-
May 5, 2026
-
Clinical Scorecard: GLP-1 Agents May Reduce Psoriasis Severity
At a Glance
| Category | Detail |
|---|
| Condition | Psoriasis |
| Key Mechanisms | Metabolic and immune effects, including reductions in inflammatory markers and changes in immune cell populations. |
| Target Population | Patients with psoriasis, particularly those with obesity or type 2 diabetes. |
| Care Setting | Dermatology and metabolic health clinics. |
Key Highlights
- GLP-1 RAs may reduce PASI scores by 40% to 80% in selected patients.
- Semaglutide and liraglutide showed significant PASI reductions in small trials.
- Adverse effects are primarily gastrointestinal; rare risks include pancreatitis.
- GLP-1 RAs can be coadministered with other psoriasis therapies.
- Current evidence is limited by small sample sizes and short follow-up durations.
Guideline-Based Recommendations
Diagnosis
- Consider metabolic comorbidities in psoriasis patients.
Management
- GLP-1 RAs may be considered as adjunct therapy in selected patients.
Monitoring & Follow-up
- Monitor for gastrointestinal adverse effects and potential rare risks.
Risks
- Potential for pancreatitis, gallbladder disease, and injection-site reactions.
Patient & Prescribing Data
Patients with psoriasis, particularly those with obesity or type 2 diabetes.
Use of GLP-1 RAs in psoriasis is off-label and primarily driven by cardiometabolic indications.
Clinical Best Practices
- Evaluate metabolic status in psoriasis patients before considering GLP-1 RA therapy.
- Monitor PASI scores and metabolic parameters during treatment.
- Educate patients on potential gastrointestinal side effects.
Related Resources & Content
